Wide Ranks

HOTH

Hoth Therapeutics, Inc.

0.8300

Top Statistics
Market Cap 5 M Forward PE -0.9540 Revenue Growth 0.00 %
Current Ratio 10.16 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 8 M Total Cash Per Share 1.16 Total Debt 33807
Total Debt To Equity 0.4510 Current Ratio 10.16 Book Value Per Share 1.09
All Measures
Short Ratio 27.00 % Message Board Id finmb_434856528 Shares Short Prior Month 313267
Return On Equity -0.8341 City New York Uuid ff6dafe1-fa0d-3a83-9121-424872ea93bf
Previous Close 0.8001 First Trade Date Epoch Utc 1 B Book Value 1.09
Total Debt 33807 Volume 124810 Price To Book 0.7643
Last Split Date 1 B Fifty Two Week Low 0.5800 Total Cash Per Share 1.16
Shares Short Previous Month Date 1 B Target Median Price 4.50 Max Age 86400
Sand P52 Week Change 0.3133 Target Mean Price 4.50 Net Income To Common -7507579
Short Percent Of Float 0.0537 Implied Shares Outstanding 6 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 2 M Average Volume10days 2 M
Total Cash 8 M Next Fiscal Year End 1 B Held Percent Insiders 0.0092
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 0.8001 Target Low Price 4.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 0.8612 Open 0.8002 Free Cashflow -5513842
State NY Dividend Yield 0.00 % Return On Assets -0.4616
Time Zone Short Name EST Trailing Eps -1.27 Day Low 0.8002
Address1 590 Madison Avenue Shares Outstanding 6 M Price Hint 4
Target High Price 5.00 Website https://hoththerapeutics.com 52 Week Change -0.2589
Average Volume 3 M Forward Eps -0.7100 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 990.10 % Last Split Factor 1:25
Regular Market Day High 0.8400 Is_sp_500 False Profit Margins 0.00 %
Debt To Equity 0.4510 Fifty Two Week High 1.73 Day High 0.8400
Shares Short 368824 Regular Market Open 0.8002 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0534
Operating Cashflow -8021644 Currency USD Time Zone Full Name America/New_York
Market Cap 5 M Is_nasdaq_100 False Zip 10022
Quote Type EQUITY Industry Biotechnology Long Name Hoth Therapeutics, Inc.
Regular Market Day Low 0.8002 Held Percent Institutions 0.0531 Current Price 0.8300
Address2 21st Floor Financial Currency USD Current Ratio 10.16
Industry Disp Biotechnology Number Of Analyst Opinions 2 Country United States
Float Shares 6 M Two Hundred Day Average 1.02 Enterprise Value -2258798
Forward PE -0.9540 Regular Market Volume 124810 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs.

It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; and HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases.

The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus.

The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003.

Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.